OpenNashEarnings

Medical Devices · NYSE: ZBH

Zimmer Biomet earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 9 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

Zimmer Biomet says its diversification strategy is working, as Hips, S.E.T. and Technology & Data grew at upper single or double digits while Knees shrank, and it extended its THINK Surgical robotics deal.

Zimmer Biomet's growth is shifting away from knees. Hips, S.E.T. and Technology & Data, Bone Cement and Surgical grew at upper single-digit or double-digit rates and together make up two-thirds of the business, while Knees declined in both the U.S. and internationally. The company extended its multi-year distribution and supply agreement with THINK Surgical, launched foot and ankle products, and opened a surgeon training facility in Charlotte.

Read the Q3 2026 summary →

Quarters

KPI history

Revenue$2.1B+3.1% y/yQ3 2026
Q4 2024: $2.0B (worked out from the annual figure)Q4 ’24$2.0BQ1 2025: $1.9BQ1 ’25$1.9BQ2 2025: $2.1BQ2 ’25$2.1BQ3 2025: $2.0BQ3 ’25$2.0BQ4 2025: $2.2B (worked out from the annual figure)Q4 ’25$2.2BQ1 2026: $2.1BQ1 ’26$2.1BQ2 2026: $2.2BQ2 ’26$2.2BQ3 2026: $2.1BQ3 ’26$2.1B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$2.0B *
Q1 2025$1.9B
Q2 2025$2.1B
Q3 2025$2.0B
Q4 2025$2.2B *
Q1 2026$2.1B
Q2 2026$2.2B
Q3 2026$2.1B
Diluted EPS (GAAP)$1.00−13.8% y/yQ3 2026
Q1 2025: $0.91Q1 ’25$0.91Q2 2025: $0.77Q2 ’25$0.77Q3 2025: $1.16Q3 ’25$1.16Q1 2026: $1.22Q1 ’26$1.22Q2 2026: $1.03Q2 ’26$1.03Q3 2026: $1.00Q3 ’26$1.00
Data
Q1 2025$0.91
Q2 2025$0.77
Q3 2025$1.16
Q1 2026$1.22
Q2 2026$1.03
Q3 2026$1.00

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin14.9%−2.7 pts y/yQ3 2026
Q4 2024: 19.2%Q4 ’2419.2%Q1 2025: 15.3%Q1 ’2515.3%Q2 2025: 14.4%Q2 ’2514.4%Q3 2025: 17.6%Q3 ’2517.6%Q4 2025: 6.9%Q4 ’256.9%Q1 2026: 17.9%Q1 ’2617.9%Q2 2026: 15.0%Q2 ’2615.0%Q3 2026: 14.9%Q3 ’2614.9%
Data
Q4 202419.2%
Q1 202515.3%
Q2 202514.4%
Q3 202517.6%
Q4 20256.9%
Q1 202617.9%
Q2 202615.0%
Q3 202614.9%
Free cash flow$484.2M+33.1% y/yQ3 2026
Q4 2024: $454.8MQ4 ’24$454.8MQ1 2025: $338.2MQ1 ’25$338.2MQ2 2025: $328.1MQ2 ’25$328.1MQ3 2025: $363.7MQ3 ’25$363.7MQ4 2025: $442.6MQ4 ’25$442.6MQ1 2026: $323.1MQ1 ’26$323.1MQ2 2026: $393.6MQ2 ’26$393.6MQ3 2026: $484.2MQ3 ’26$484.2M
Data
Q4 2024$454.8M
Q1 2025$338.2M
Q2 2025$328.1M
Q3 2025$363.7M
Q4 2025$442.6M
Q1 2026$323.1M
Q2 2026$393.6M
Q3 2026$484.2M

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Revenue$2.0Bd$1.9B$2.1B$2.0B$2.2Bd$2.1B$2.2B$2.1B
Operating income$389.0Md$292.3M$300.0M$351.3M$154.5Md$373.2M$326.1M$307.6M
Operating margin19.2%15.3%14.4%17.6%6.9%17.9%15.0%14.9%
Net income$239.5Md$182.0M$152.8M$230.9M$139.3Md$238.1M$198.3M$191.6M
Diluted EPS—$0.91$0.77$1.16—$1.22$1.03$1.00
Operating cash flow$506.3Md$382.8M$378.2Md$418.7Md$517.4Md$359.4M$447.8Md$560.0Md
Capital expenditure$51.5Md$44.6M$50.1Md$55.0Md$74.8Md$36.3M$54.2Md$75.8Md
Free cash flow$454.8M$338.2M$328.1M$363.7M$442.6M$323.1M$393.6M$484.2M
R&D expense$108.5Md$110.6M$113.3M$115.9M$118.7Md$103.4M$104.8M$105.9M

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings